Table 1.
Characteristics of adult allogeneic HCT recipients transplanted between January 2007 and December 2016 with lab‐confirmed Gram‐negative rod bacteremia by majority antibiotic treatment setting
| Total (n = 238) | Majority outpatient treatment (n = 136)a | Majority inpatient treatment (n = 102)b | |
|---|---|---|---|
| Age (years)—median, 1st–3rd Quartile | 53 (43–60) | 51 (42–59) | 54 (45–61) |
| Male—N, % | 117 (49.2) | 64 (47.1) | 53 (52.0) |
| Race/ethnicity—N, % | |||
| Asian/Pacific Islander | 16 (6.7) | 8 (5.9) | 8 (7.8) |
| Black | 8 (3.4) | 4 (2.9) | 4 (3.9) |
| Caucasian | 169 (71.0) | 97 (71.3) | 72 (70.6) |
| Hispanic | 20 (8.4) | 12 (8.8) | 8 (7.8) |
| Other | 25 (10.5) | 15 (11.0) | 10 (9.8) |
| Underlying disease—N, % | |||
| Acute lymphoid leukemia | 37 (15.5) | 21 (15.4) | 16 (15.7) |
| Acute myeloid leukemia | 84 (35.3) | 45 (33.1) | 39 (38.2) |
| Myelodysplastic syndromes | 41 (17.2) | 15 (11.0) | 26 (25.5) |
| Multiple myeloma | 12 (5.0) | 10 (7.4) | 2 (2.0) |
| Non‐Hodgkin lympoma | 27 (11.3) | 18 (13.2) | 9 (8.8) |
| Other | 37 (15.5) | 27 (19.9) | 10 (9.8) |
| Unrelated donor—N, % | 159 (66.8) | 83 (61.0) | 76 (74.5) |
| Comorbidity Index (HCT‐CI)—median, IQR* | 7 (4–8) | 7 (6–8) | 7 (4–8) |
| Severe Acute GVHD (≥Grade 3)—N, % | 50 (21.0) | 14 (10.3) | 36 (35.3) |
| Polymicrobial bacteremia—N, % | 23 (9.7) | 17 (12.5) | 6 (5.9) |
| Hard‐to‐treat organism—N, % | 9 (3.8) | 2 (1.5) | 7 (6.9) |
| Myeloablative conditioning regiment—N, % | 90 (37.8) | 48 (35.3) | 42 (41.2) |
| Neutropenia (<500 cells/ml)—N, % | 60 (25.2) | 16 (11.8) | 44 (43.1) |
| Days till first GNRB—median, IQR | 51 (14–756) | 57 (34–80) | 35 (7–62) |
Note: *Data limited to the 199 individuals with scores.
Abbreviations: GVHD, Graft‐versus‐host disease; HCT, hematopoietic cell transplant; IQR, interquartile range.
a
Defined people who spent more than 7 of their 14 days outpatient.
b
Defined people who spent more than 7 of their 14 days inpatient.